APO Research
Talk to an analyst

APO RESEARCH · REPORT

Colorectal Cancer Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Colorectal Cancer Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

20 December 2025195 pages

Choose your research edition.

Industry ResearchColorectal Cancer Drugs Industry Research Report 2026136 pages · $2,950 USDIndustry Growth & TrendsGlobal Colorectal Cancer Drugs Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal Colorectal Cancer Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Colorectal Cancer Drugs Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Colorectal Cancer Drugs Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

The global Colorectal Cancer Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Colorectal Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Colorectal Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Colorectal Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Colorectal Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Colorectal Cancer Drugs include Sanofi, Merck & Co., Inc., Roch, Bayer, Amgen, Vaccinogen, Taiho Pharmaceutical, Sumitomo Dainippon and Regeneron, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Colorectal Cancer Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Colorectal Cancer Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Colorectal Cancer Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Colorectal Cancer Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Colorectal Cancer Drugs Segment by Company

Sanofi

Merck & Co., Inc.

Roch

Bayer

Amgen

Vaccinogen

Taiho Pharmaceutical

Sumitomo Dainippon

Regeneron

Mologen

Hutchison MediPharma

Elli Lilly

Bristol-Myers Squibb

Boehringer Ingelheim

Array BioPharma

AB Science

Colorectal Cancer Drugs Segment by Type

BRAF or MEK Inhibitors

Epidermal Growth Factor Receptor (EGFR) Inhibitors

Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors

Tyrosine Kinase (TKI) Inhibitors

Immunomodulators

Vascular Endothelial Growth Factor (VEGF) Inhibitors

Colorectal Cancer Drugs Segment by Application

Radiotherapy

Chemotherapy

Colorectal Cancer Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Colorectal Cancer Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Colorectal Cancer Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Colorectal Cancer Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Colorectal Cancer Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Colorectal Cancer Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Colorectal Cancer Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Colorectal Cancer Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Colorectal Cancer Drugs Industry Trends Table 2. Colorectal Cancer Drugs Industry Drivers Table 3. Colorectal Cancer Drugs Industry Opportunities and Challenges Table 4. Colorectal Cancer Drugs Industry Restraints Table 5. Global Colorectal Cancer Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Colorectal Cancer Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Colorectal Cancer Drugs Sales by Manufacturers (units) & (2021-2026) Table 8. Global Colorectal Cancer Drugs Sales Market Share by Manufacturers Table 9. Global Colorectal Cancer Drugs Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Colorectal Cancer Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Colorectal Cancer Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Colorectal Cancer Drugs Manufacturers, Product Type & Application Table 13. Global Colorectal Cancer Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Colorectal Cancer Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of BRAF or MEK Inhibitors Table 17. Major Manufacturers of Epidermal Growth Factor Receptor (EGFR) Inhibitors Table 18. Major Manufacturers of Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors Table 19. Major Manufacturers of Tyrosine Kinase (TKI) Inhibitors Table 20. Major Manufacturers of Immunomodulators Table 21. Major Manufacturers of Vascular Endothelial Growth Factor (VEGF) Inhibitors Table 22. Global Colorectal Cancer Drugs Sales by Type 2021 VS 2025 VS 2032 (units) Table 23. Global Colorectal Cancer Drugs Sales by Type (2021-2026) & (units) Table 24. Global Colorectal Cancer Drugs Sales by Type (2027-2032) & (units) Table 25. Global Colorectal Cancer Drugs Sales Market Share by Type (2021-2026) Table 26. Global Colorectal Cancer Drugs Sales Market Share by Type (2027-2032) Table 27. Global Colorectal Cancer Drugs Revenue by Type 2021 VS 2025 VS 2032 (units) Table 28. Global Colorectal Cancer Drugs Revenue by Type (2021-2026) & (units) Table 29. Global Colorectal Cancer Drugs Revenue by Type (2027-2032) & (units) Table 30. Global Colorectal Cancer Drugs Revenue Market Share by Type (2021-2026) Table 31. Global Colorectal Cancer Drugs Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Radiotherapy Table 33. Major Manufacturers of Chemotherapy Table 34. Global Colorectal Cancer Drugs Sales by Application 2021 VS 2025 VS 2032 (units) Table 35. Global Colorectal Cancer Drugs Sales by Application (2021-2026) & (units) Table 36. Global Colorectal Cancer Drugs Sales by Application (2027-2032) & (units) Table 37. Global Colorectal Cancer Drugs Sales Market Share by Application (2021-2026) Table 38. Global Colorectal Cancer Drugs Sales Market Share by Application (2027-2032) Table 39. Global Colorectal Cancer Drugs Revenue by Application 2021 VS 2025 VS 2032 (units) Table 40. Global Colorectal Cancer Drugs Revenue by Application (2021-2026) & (units) Table 41. Global Colorectal Cancer Drugs Revenue by Application (2027-2032) & (units) Table 42. Global Colorectal Cancer Drugs Revenue Market Share by Application (2021-2026) Table 43. Global Colorectal Cancer Drugs Revenue Market Share by Application (2027-2032) Table 44. Global Colorectal Cancer Drugs Sales by Region: 2021 VS 2025 VS 2032 (units) Table 45. Global Colorectal Cancer Drugs Sales by Region (2021-2026) & (units) Table 46. Global Colorectal Cancer Drugs Sales Market Share by Region (2021-2026) Table 47. Global Colorectal Cancer Drugs Sales Forecasted by Region (2027-2032) & (units) Table 48. Global Colorectal Cancer Drugs Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Colorectal Cancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (units) Table 50. North America Colorectal Cancer Drugs Sales by Country (2021-2026) & (units) Table 51. North America Colorectal Cancer Drugs Sales by Country (2027-2032) & (units) Table 52. Europe Colorectal Cancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (units) Table 53. Europe Colorectal Cancer Drugs Sales by Country (2021-2026) & (units) Table 54. Europe Colorectal Cancer Drugs Sales by Country (2027-2032) & (units) Table 55. Asia Pacific Colorectal Cancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (units) Table 56. Asia Pacific Colorectal Cancer Drugs Sales by Country (2021-2026) & (units) Table 57. Asia Pacific Colorectal Cancer Drugs Sales by Country (2027-2032) & (units) Table 58. South America, Middle East and Africa Colorectal Cancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (units) Table 59. South America, Middle East and Africa Colorectal Cancer Drugs Sales by Country (2021-2026) & (units) Table 60. South America, Middle East and Africa Colorectal Cancer Drugs Sales by Country (2027-2032) & (units) Table 61. Global Colorectal Cancer Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Colorectal Cancer Drugs Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Colorectal Cancer Drugs Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Colorectal Cancer Drugs Revenue Market Share by Region (2021-2026) Table 65. Global Colorectal Cancer Drugs Revenue Market Share by Region (2027-2032) Table 66. Sanofi Company Information Table 67. Sanofi Business Overview Table 68. Sanofi Colorectal Cancer Drugs Sales (units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Sanofi Colorectal Cancer Drugs Product Portfolio Table 70. Sanofi Recent Development Table 71. Merck & Co., Inc. Company Information Table 72. Merck & Co., Inc. Business Overview Table 73. Merck & Co., Inc. Colorectal Cancer Drugs Sales (units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Merck & Co., Inc. Colorectal Cancer Drugs Product Portfolio Table 75. Merck & Co., Inc. Recent Development Table 76. Roch Company Information Table 77. Roch Business Overview Table 78. Roch Colorectal Cancer Drugs Sales (units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Roch Colorectal Cancer Drugs Product Portfolio Table 80. Roch Recent Development Table 81. Bayer Company Information Table 82. Bayer Business Overview Table 83. Bayer Colorectal Cancer Drugs Sales (units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Bayer Colorectal Cancer Drugs Product Portfolio Table 85. Bayer Recent Development Table 86. Amgen Company Information Table 87. Amgen Business Overview Table 88. Amgen Colorectal Cancer Drugs Sales (units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Amgen Colorectal Cancer Drugs Product Portfolio Table 90. Amgen Recent Development Table 91. Vaccinogen Company Information Table 92. Vaccinogen Business Overview Table 93. Vaccinogen Colorectal Cancer Drugs Sales (units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Vaccinogen Colorectal Cancer Drugs Product Portfolio Table 95. Vaccinogen Recent Development Table 96. Taiho Pharmaceutical Company Information Table 97. Taiho Pharmaceutical Business Overview Table 98. Taiho Pharmaceutical Colorectal Cancer Drugs Sales (units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Taiho Pharmaceutical Colorectal Cancer Drugs Product Portfolio Table 100. Taiho Pharmaceutical Recent Development Table 101. Sumitomo Dainippon Company Information Table 102. Sumitomo Dainippon Business Overview Table 103. Sumitomo Dainippon Colorectal Cancer Drugs Sales (units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Sumitomo Dainippon Colorectal Cancer Drugs Product Portfolio Table 105. Sumitomo Dainippon Recent Development Table 106. Regeneron Company Information Table 107. Regeneron Business Overview Table 108. Regeneron Colorectal Cancer Drugs Sales (units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Regeneron Colorectal Cancer Drugs Product Portfolio Table 110. Regeneron Recent Development Table 111. Mologen Company Information Table 112. Mologen Business Overview Table 113. Mologen Colorectal Cancer Drugs Sales (units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Mologen Colorectal Cancer Drugs Product Portfolio Table 115. Mologen Recent Development Table 116. Hutchison MediPharma Company Information Table 117. Hutchison MediPharma Business Overview Table 118. Hutchison MediPharma Colorectal Cancer Drugs Sales (units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. Hutchison MediPharma Colorectal Cancer Drugs Product Portfolio Table 120. Hutchison MediPharma Recent Development Table 121. Elli Lilly Company Information Table 122. Elli Lilly Business Overview Table 123. Elli Lilly Colorectal Cancer Drugs Sales (units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. Elli Lilly Colorectal Cancer Drugs Product Portfolio Table 125. Elli Lilly Recent Development Table 126. Bristol-Myers Squibb Company Information Table 127. Bristol-Myers Squibb Business Overview Table 128. Bristol-Myers Squibb Colorectal Cancer Drugs Sales (units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. Bristol-Myers Squibb Colorectal Cancer Drugs Product Portfolio Table 130. Bristol-Myers Squibb Recent Development Table 131. Boehringer Ingelheim Company Information Table 132. Boehringer Ingelheim Business Overview Table 133. Boehringer Ingelheim Colorectal Cancer Drugs Sales (units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 134. Boehringer Ingelheim Colorectal Cancer Drugs Product Portfolio Table 135. Boehringer Ingelheim Recent Development Table 136. Array BioPharma Company Information Table 137. Array BioPharma Business Overview Table 138. Array BioPharma Colorectal Cancer Drugs Sales (units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 139. Array BioPharma Colorectal Cancer Drugs Product Portfolio Table 140. Array BioPharma Recent Development Table 141. AB Science Company Information Table 142. AB Science Business Overview Table 143. AB Science Colorectal Cancer Drugs Sales (units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 144. AB Science Colorectal Cancer Drugs Product Portfolio Table 145. AB Science Recent Development Table 146. Key Raw Materials Table 147. Raw Materials Key Suppliers Table 148. Colorectal Cancer Drugs Distributors List Table 149. Colorectal Cancer Drugs Customers List Table 150. Research Programs/Design for This Report Table 151. Authors List of This Report Table 152. Secondary Sources Table 153. Primary Sources List of Figures Figure 1. Colorectal Cancer Drugs Product Image Figure 2. Global Colorectal Cancer Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Colorectal Cancer Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Colorectal Cancer Drugs Sales (2021-2032) & (units) Figure 5. Global Colorectal Cancer Drugs Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Colorectal Cancer Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. BRAF or MEK Inhibitors Image Figure 9. Epidermal Growth Factor Receptor (EGFR) Inhibitors Image Figure 10. Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors Image Figure 11. Tyrosine Kinase (TKI) Inhibitors Image Figure 12. Immunomodulators Image Figure 13. Vascular Endothelial Growth Factor (VEGF) Inhibitors Image Figure 14. Global Colorectal Cancer Drugs Sales by Type (2021 VS 2025 VS 2032) & (units) Figure 15. Global Colorectal Cancer Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global Colorectal Cancer Drugs Sales Market Share by Type (2021-2032) Figure 17. Global Colorectal Cancer Drugs Revenue by Type (2021 VS 2025 VS 2032) & (units) Figure 18. Global Colorectal Cancer Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Colorectal Cancer Drugs Revenue Market Share by Type (2021-2032) Figure 20. Radiotherapy Image Figure 21. Chemotherapy Image Figure 22. Global Colorectal Cancer Drugs Sales by Application (2021 VS 2025 VS 2032) & (units) Figure 23. Global Colorectal Cancer Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Colorectal Cancer Drugs Sales Market Share by Application (2021-2032) Figure 25. Global Colorectal Cancer Drugs Revenue by Application (2021 VS 2025 VS 2032) & (units) Figure 26. Global Colorectal Cancer Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Colorectal Cancer Drugs Revenue Market Share by Application (2021-2032) Figure 28. North America Colorectal Cancer Drugs Sales and Growth Rate (2021-2032) & (units) Figure 29. North America Colorectal Cancer Drugs Sales Market Share by Country (2021-2032) Figure 30. U.S. Colorectal Cancer Drugs Sales and Growth Rate (2021-2032) & (units) Figure 31. Canada Colorectal Cancer Drugs Sales and Growth Rate (2021-2032) & (units) Figure 32. Mexico Colorectal Cancer Drugs Sales and Growth Rate (2021-2032) & (units) Figure 33. Europe Colorectal Cancer Drugs Sales and Growth Rate (2021-2032) & (units) Figure 34. Europe Colorectal Cancer Drugs Sales Market Share by Country (2021-2032) Figure 35. Germany Colorectal Cancer Drugs Sales and Growth Rate (2021-2032) & (units) Figure 36. France Colorectal Cancer Drugs Sales and Growth Rate (2021-2032) & (units) Figure 37. U.K. Colorectal Cancer Drugs Sales and Growth Rate (2021-2032) & (units) Figure 38. Italy Colorectal Cancer Drugs Sales and Growth Rate (2021-2032) & (units) Figure 39. Netherlands Colorectal Cancer Drugs Sales and Growth Rate (2021-2032) & (units) Figure 40. Asia Pacific Colorectal Cancer Drugs Sales and Growth Rate (2021-2032) & (units) Figure 41. Asia Pacific Colorectal Cancer Drugs Sales Market Share by Country (2021-2032) Figure 42. China Colorectal Cancer Drugs Sales and Growth Rate (2021-2032) & (units) Figure 43. Japan Colorectal Cancer Drugs Sales and Growth Rate (2021-2032) & (units) Figure 44. South Korea Colorectal Cancer Drugs Sales and Growth Rate (2021-2032) & (units) Figure 45. Southeast Asia Colorectal Cancer Drugs Sales and Growth Rate (2021-2032) & (units) Figure 46. India Colorectal Cancer Drugs Sales and Growth Rate (2021-2032) & (units) Figure 47. Australia Colorectal Cancer Drugs Sales and Growth Rate (2021-2032) & (units) Figure 48. South America, Middle East and Africa Colorectal Cancer Drugs Sales and Growth Rate (2021-2032) & (units) Figure 49. South America, Middle East and Africa Colorectal Cancer Drugs Sales Market Share by Country (2021-2032) Figure 50. Brazil Colorectal Cancer Drugs Sales and Growth Rate (2021-2032) & (units) Figure 51. South Africa Colorectal Cancer Drugs Sales and Growth Rate (2021-2032) & (units) Figure 52. Saudi Arabia Colorectal Cancer Drugs Sales and Growth Rate (2021-2032) & (units) Figure 53. Turkey Colorectal Cancer Drugs Sales and Growth Rate (2021-2032) & (units) Figure 54. Argentina Colorectal Cancer Drugs Sales and Growth Rate (2021-2032) & (units) Figure 55. UAE Colorectal Cancer Drugs Sales and Growth Rate (2021-2032) & (units) Figure 56. Egypt Colorectal Cancer Drugs Sales and Growth Rate (2021-2032) & (units) Figure 57. Chile Colorectal Cancer Drugs Sales and Growth Rate (2021-2032) & (units) Figure 58. Global Colorectal Cancer Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Colorectal Cancer Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Colorectal Cancer Drugs Revenue (2021-2032) & (US$ Million) Figure 61. North America Colorectal Cancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Colorectal Cancer Drugs Revenue (2021-2032) & (US$ Million) Figure 63. Europe Colorectal Cancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Colorectal Cancer Drugs Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Colorectal Cancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Colorectal Cancer Drugs Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Colorectal Cancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Colorectal Cancer Drugs Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Colorectal Cancer Drugs Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • BRAF or MEK Inhibitors
  • Epidermal Growth Factor Receptor (EGFR) Inhibitors
  • Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors
  • Tyrosine Kinase (TKI) Inhibitors
  • Immunomodulators
  • Vascular Endothelial Growth Factor (VEGF) Inhibitors
Applications
  • Radiotherapy
  • Chemotherapy
Companies covered
  • Sanofi
  • Merck & Co., Inc.
  • Roch
  • Bayer
  • Amgen
  • Vaccinogen
  • Taiho Pharmaceutical
  • Sumitomo Dainippon
  • Regeneron
  • Mologen
  • Hutchison MediPharma
  • Elli Lilly
  • Bristol-Myers Squibb
  • Boehringer Ingelheim
  • Array BioPharma
  • AB Science

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Colorectal Cancer Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Colorectal Cancer Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Colorectal Cancer Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Colorectal Cancer Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Colorectal Cancer Drugs Market Dynamics
  1. 2.1 Colorectal Cancer Drugs Industry Trends
  2. 2.2 Colorectal Cancer Drugs Industry Drivers
  3. 2.3 Colorectal Cancer Drugs Industry Opportunities and Challenges
  4. 2.4 Colorectal Cancer Drugs Industry Restraints
3 Colorectal Cancer Drugs Market by Manufacturers
  1. 3.1 Global Colorectal Cancer Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Colorectal Cancer Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Colorectal Cancer Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Colorectal Cancer Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Colorectal Cancer Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Colorectal Cancer Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Colorectal Cancer Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Colorectal Cancer Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Colorectal Cancer Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Colorectal Cancer Drugs Tier 1, Tier 2, and Tier 3
4 Colorectal Cancer Drugs Market by Type
  1. 4.1 Colorectal Cancer Drugs Type Introduction
  2. 4.1.1 BRAF or MEK Inhibitors
  3. 4.1.2 Epidermal Growth Factor Receptor (EGFR) Inhibitors
  4. 4.1.3 Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors
  5. 4.1.4 Tyrosine Kinase (TKI) Inhibitors
  6. 4.1.5 Immunomodulators
  7. 4.1.6 Vascular Endothelial Growth Factor (VEGF) Inhibitors
  8. 4.2 Global Colorectal Cancer Drugs Sales by Type
  9. 4.2.1 Global Colorectal Cancer Drugs Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Colorectal Cancer Drugs Sales by Type (2021-2032)
  11. 4.2.3 Global Colorectal Cancer Drugs Sales Market Share by Type (2021-2032)
  12. 4.3 Global Colorectal Cancer Drugs Revenue by Type
  13. 4.3.1 Global Colorectal Cancer Drugs Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Colorectal Cancer Drugs Revenue by Type (2021-2032)
  15. 4.3.3 Global Colorectal Cancer Drugs Revenue Market Share by Type (2021-2032)
5 Colorectal Cancer Drugs Market by Application
  1. 5.1 Colorectal Cancer Drugs Application Introduction
  2. 5.1.1 Radiotherapy
  3. 5.1.2 Chemotherapy
  4. 5.2 Global Colorectal Cancer Drugs Sales by Application
  5. 5.2.1 Global Colorectal Cancer Drugs Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Colorectal Cancer Drugs Sales by Application (2021-2032)
  7. 5.2.3 Global Colorectal Cancer Drugs Sales Market Share by Application (2021-2032)
  8. 5.3 Global Colorectal Cancer Drugs Revenue by Application
  9. 5.3.1 Global Colorectal Cancer Drugs Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Colorectal Cancer Drugs Revenue by Application (2021-2032)
  11. 5.3.3 Global Colorectal Cancer Drugs Revenue Market Share by Application (2021-2032)
6 Global Colorectal Cancer Drugs Sales by Region
  1. 6.1 Global Colorectal Cancer Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Colorectal Cancer Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Colorectal Cancer Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Colorectal Cancer Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Colorectal Cancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Colorectal Cancer Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Colorectal Cancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Colorectal Cancer Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Colorectal Cancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Colorectal Cancer Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Colorectal Cancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Colorectal Cancer Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Colorectal Cancer Drugs Revenue by Region
  1. 7.1 Global Colorectal Cancer Drugs Revenue by Region
  2. 7.1.1 Global Colorectal Cancer Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Colorectal Cancer Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Colorectal Cancer Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Colorectal Cancer Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Colorectal Cancer Drugs Revenue (2021-2032)
  8. 7.2.2 North America Colorectal Cancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Colorectal Cancer Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Colorectal Cancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Colorectal Cancer Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Colorectal Cancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Colorectal Cancer Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Colorectal Cancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Colorectal Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Colorectal Cancer Drugs Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Merck & Co., Inc.
  8. 8.2.1 Merck & Co., Inc. Company Information
  9. 8.2.2 Merck & Co., Inc. Business Overview
  10. 8.2.3 Merck & Co., Inc. Colorectal Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck & Co., Inc. Colorectal Cancer Drugs Product Portfolio
  12. 8.2.5 Merck & Co., Inc. Recent Developments
  13. 8.3 Roch
  14. 8.3.1 Roch Company Information
  15. 8.3.2 Roch Business Overview
  16. 8.3.3 Roch Colorectal Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Roch Colorectal Cancer Drugs Product Portfolio
  18. 8.3.5 Roch Recent Developments
  19. 8.4 Bayer
  20. 8.4.1 Bayer Company Information
  21. 8.4.2 Bayer Business Overview
  22. 8.4.3 Bayer Colorectal Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bayer Colorectal Cancer Drugs Product Portfolio
  24. 8.4.5 Bayer Recent Developments
  25. 8.5 Amgen
  26. 8.5.1 Amgen Company Information
  27. 8.5.2 Amgen Business Overview
  28. 8.5.3 Amgen Colorectal Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Amgen Colorectal Cancer Drugs Product Portfolio
  30. 8.5.5 Amgen Recent Developments
  31. 8.6 Vaccinogen
  32. 8.6.1 Vaccinogen Company Information
  33. 8.6.2 Vaccinogen Business Overview
  34. 8.6.3 Vaccinogen Colorectal Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Vaccinogen Colorectal Cancer Drugs Product Portfolio
  36. 8.6.5 Vaccinogen Recent Developments
  37. 8.7 Taiho Pharmaceutical
  38. 8.7.1 Taiho Pharmaceutical Company Information
  39. 8.7.2 Taiho Pharmaceutical Business Overview
  40. 8.7.3 Taiho Pharmaceutical Colorectal Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Taiho Pharmaceutical Colorectal Cancer Drugs Product Portfolio
  42. 8.7.5 Taiho Pharmaceutical Recent Developments
  43. 8.8 Sumitomo Dainippon
  44. 8.8.1 Sumitomo Dainippon Company Information
  45. 8.8.2 Sumitomo Dainippon Business Overview
  46. 8.8.3 Sumitomo Dainippon Colorectal Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Sumitomo Dainippon Colorectal Cancer Drugs Product Portfolio
  48. 8.8.5 Sumitomo Dainippon Recent Developments
  49. 8.9 Regeneron
  50. 8.9.1 Regeneron Company Information
  51. 8.9.2 Regeneron Business Overview
  52. 8.9.3 Regeneron Colorectal Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Regeneron Colorectal Cancer Drugs Product Portfolio
  54. 8.9.5 Regeneron Recent Developments
  55. 8.10 Mologen
  56. 8.10.1 Mologen Company Information
  57. 8.10.2 Mologen Business Overview
  58. 8.10.3 Mologen Colorectal Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Mologen Colorectal Cancer Drugs Product Portfolio
  60. 8.10.5 Mologen Recent Developments
  61. 8.11 Hutchison MediPharma
  62. 8.11.1 Hutchison MediPharma Company Information
  63. 8.11.2 Hutchison MediPharma Business Overview
  64. 8.11.3 Hutchison MediPharma Colorectal Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Hutchison MediPharma Colorectal Cancer Drugs Product Portfolio
  66. 8.11.5 Hutchison MediPharma Recent Developments
  67. 8.12 Elli Lilly
  68. 8.12.1 Elli Lilly Company Information
  69. 8.12.2 Elli Lilly Business Overview
  70. 8.12.3 Elli Lilly Colorectal Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Elli Lilly Colorectal Cancer Drugs Product Portfolio
  72. 8.12.5 Elli Lilly Recent Developments
  73. 8.13 Bristol-Myers Squibb
  74. 8.13.1 Bristol-Myers Squibb Company Information
  75. 8.13.2 Bristol-Myers Squibb Business Overview
  76. 8.13.3 Bristol-Myers Squibb Colorectal Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Bristol-Myers Squibb Colorectal Cancer Drugs Product Portfolio
  78. 8.13.5 Bristol-Myers Squibb Recent Developments
  79. 8.14 Boehringer Ingelheim
  80. 8.14.1 Boehringer Ingelheim Company Information
  81. 8.14.2 Boehringer Ingelheim Business Overview
  82. 8.14.3 Boehringer Ingelheim Colorectal Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Boehringer Ingelheim Colorectal Cancer Drugs Product Portfolio
  84. 8.14.5 Boehringer Ingelheim Recent Developments
  85. 8.15 Array BioPharma
  86. 8.15.1 Array BioPharma Company Information
  87. 8.15.2 Array BioPharma Business Overview
  88. 8.15.3 Array BioPharma Colorectal Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Array BioPharma Colorectal Cancer Drugs Product Portfolio
  90. 8.15.5 Array BioPharma Recent Developments
  91. 8.16 AB Science
  92. 8.16.1 AB Science Company Information
  93. 8.16.2 AB Science Business Overview
  94. 8.16.3 AB Science Colorectal Cancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 AB Science Colorectal Cancer Drugs Product Portfolio
  96. 8.16.5 AB Science Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Colorectal Cancer Drugs Value Chain Analysis
  2. 9.1.1 Colorectal Cancer Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Colorectal Cancer Drugs Production Mode & Process
  6. 9.2 Colorectal Cancer Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Colorectal Cancer Drugs Distributors
  9. 9.2.3 Colorectal Cancer Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst